SCHEMBL8611986

SCHEMBL8611986

NNC(=O)c1ccc(C(=O)NCc2ccc(S(=O)(=O)NCCOCCO)cc2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
NAMPT P43490 3/20 0.41
USP2 O75604 1/20 0.41
F2 P00734 2/20 0.39
TMPRSS6 Q8IU80 2/20 0.39
HDAC3 O15379 3/20 0.39
HDAC1 Q13547 3/20 0.39
HDAC4 P56524 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CDK1 P06493 1/20 0.39
CDK2 P24941 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CXCR4 P61073 1/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15259137 0.93 CDK1 (0.42) ALDH1A1NAMPTUSP2F2TMPRSS6
SCHEMBL8612098 0.90 NAMPT (0.45) ALDH1A1NAMPTUSP2HDAC3HDAC1
SCHEMBL8611980 0.82 SMN1; SMN2 (0.44) HDAC3HDAC1HDAC4HDAC6CA1
SCHEMBL15947351 0.75 ALDH1A1 (0.57) ALDH1A1NAMPTUSP2MEN1KMT2A
SCHEMBL8404645 0.75 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ACDK1CDK2
SCHEMBL15259128 0.75 EPHX2 (0.43) HDAC3HDAC1HDAC4HDAC6CA1
SCHEMBL17715304 0.74 SGMS1 (0.33) NAMPTMEN1KMT2ACDK1CDK2
SCHEMBL8592233 0.73 SMN1; SMN2 (0.46) ALDH1A1NAMPTHDAC3HDAC1HDAC4
SCHEMBL14853588 0.72 ALDH1A1 (0.54) ALDH1A1NAMPTUSP2MEN1KMT2A
SCHEMBL5893917 0.72 ALDH1A1 (0.59) ALDH1A1CDK1CDK2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328085-B2 Heterocyclic compounds and expansion agents for hematopoietic stem cells NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-05-03 US disclosed
US-20130245255-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-09-19 US disclosed
US-20120128640-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245255-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS HCLS1, RUNX1, RCC1 ALDH1A1 291/4885NAMPT 980/4885USP2 3893/4885
US-20120128640-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS HCLS1, RUNX1, RCC1 ALDH1A1 291/4885NAMPT 980/4885USP2 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.